Måndag 30 December | 16:34:53 Europe / Stockholm
Svenska | English

Faron Pharmaceuticals

Kalender

Tid*
2025-08-27 08:00 Kvartalsrapport 2025-Q2
2025-03-21 N/A Årsstämma
2025-02-27 08:00 Bokslutskommuniké 2024
2024-08-28 - Kvartalsrapport 2024-Q2
2024-03-25 - X-dag ordinarie utdelning FARON 0.00 EUR
2024-03-22 - Årsstämma
2024-03-14 - Bokslutskommuniké 2023
2023-08-29 - Kvartalsrapport 2023-Q2
2023-03-27 - X-dag ordinarie utdelning FARON 0.00 EUR
2023-03-24 - Årsstämma
2023-03-03 - Bokslutskommuniké 2022
2022-08-25 - Kvartalsrapport 2022-Q2
2022-07-07 - Extra Bolagsstämma 2022
2022-04-25 - X-dag ordinarie utdelning FARON 0.00 EUR
2022-04-22 - Årsstämma
2022-03-25 - Bokslutskommuniké 2021
2021-08-26 - Kvartalsrapport 2021-Q2
2021-04-26 - X-dag ordinarie utdelning FARON 0.00 EUR
2021-04-23 - Årsstämma
2021-03-25 - Bokslutskommuniké 2020
2020-05-14 - X-dag ordinarie utdelning FARON 0.00 EUR
2020-05-13 - Årsstämma
2020-03-20 - Bokslutskommuniké 2019

Beskrivning

LandFinland
ListaFirst North Finland
SektorHälsovård
IndustriBioteknik
Faron Pharmaceuticals är verksamt inom medicinteknik. Bolaget bedriver forskning och utveckling av terapeutiska lösningar som används för behandling av immuna sjukdomar och diverse organskador. Störst verksamhet återfinns inom Nordamerika samt Europa, med sjukhus och forskningsinstitut som dominerande kundbas. Utöver huvudverksamheten erbjuds diverse mervärdestjänster. Huvudkontoret ligger i Turku.
Filter arrow-icon
År arrow-icon
Typ arrow-icon
Språk arrow-icon
Rensa
Se endast PM som skrivits på följande språk
Se endast PM som skrivits från valt år
Se endast PM som skrivits på följande språk
2024-12-13 08:00:02 Faron’s Financial Calendar for 2025 2,04 EUR | +2,45%  | 0,33 MEUR
2024-12-13 08:00:00 Faron Pharmaceuticals Oy: Faron's Financial Calendar for 2025 2,04 EUR | +2,45%  | 0,33 MEUR pdf download
2024-12-10 08:00:07 Faron presents BEXMAB data at ASH Annual Meeting 2,24 EUR | -4,68%  | 1,18 MEUR
2024-12-10 08:00:00 Faron Pharmaceuticals Oy: Faron presents BEXMAB data at ASH Annual Meeting 2,24 EUR | -4,68%  | 1,18 MEUR pdf download
2024-12-02 09:00:00 Interactions with UK Regulatory Authorities 2,25 EUR | +10,57%  | 1,00 MEUR
2024-12-02 09:00:00 Faron Pharmaceuticals Oy: Interactions with UK Regulatory Authorities 2,25 EUR | +10,57%  | 1,00 MEUR pdf download
2024-11-27 08:00:10 Positive Phase 2 Interim Results from BEXMAB Trial 2,14 EUR | +10,88%  | 1,11 MEUR
2024-11-11 08:00:10 Targeting Soluble Clever-1 for Autoimmune Diseases 1,93 EUR | +1,26%  | 0,72 MEUR
2024-11-05 08:00:03 Shareholders’ Nomination Board 1,86 EUR | -1,17%  | 0,38 MEUR
2024-10-22 08:00:03 Faron’s Capital Markets Day 2024 2,16 EUR | -12,37%  | 1,99 MEUR
2024-10-07 08:00:09 Faron announces Capital Markets Day 2,68 EUR | +2,88%  | 0,40 MEUR
2024-08-30 08:00:14 Grant of options 2,46 EUR | -1,40%  | 0,54 MEUR pdf download
2024-08-27 08:00:12 Faron 2024 Half-Year Financial Results 2,70 EUR | +14,65%  | 2,24 MEUR pdf download
2024-08-27 08:00:12 FDA Grants Fast Track Designation for Bexmarilimab 2,70 EUR | +14,65%  | 2,24 MEUR
2024-08-20 08:00:17 Notice of Half-Year Financial Results 2,00 EUR | -2,91%  | 0,30 MEUR
2024-08-13 08:00:12 Traumakine Research Collaboration and DoD Grant 2,21 EUR | +1,84%  | 0,42 MEUR
2024-08-08 08:00:13 Appointment of Chief Financial Officer 2,13 EUR | +7,58%  | 0,65 MEUR
2024-08-07 11:00:00 Grant of options 1,98 EUR | +1,96%  | 0,21 MEUR
2024-08-06 09:30:00 Faron Appoints Dr. Petri Bono as new CMO 1,94 EUR | +6,24%  | 0,52 MEUR
2024-07-11 08:00:07 Faron Announces Positive FDA Feedback 1,58 EUR | +29,18%  | 1,80 MEUR
2024-06-25 15:00:00 Update on settlement 1,18 EUR | +4,63%  | 0,57 MEUR
2024-06-25 11:30:01 Holding(s) in Company - Replacement 1,18 EUR | +4,63%  | 0,57 MEUR
2024-06-24 13:45:01 Holding(s) in Company 1,12 EUR | -1,40%  | 0,83 MEUR
2024-06-24 13:45:01 Holding(s) in Company 1,12 EUR | -1,40%  | 0,83 MEUR
2024-06-24 13:45:01 Holding(s) in Company 1,12 EUR | -1,40%  | 0,83 MEUR
2024-06-24 13:45:01 Holding(s) in Company 1,12 EUR | -1,40%  | 0,83 MEUR
2024-06-20 14:00:00 New shares registered with Finnish Trade Register 1,14 EUR | +8,16%  | 19,2 MEUR
2024-06-20 08:00:08 Fully subscribed EUR 30.7 million share offering 1,14 EUR | +8,16%  | 19,2 MEUR
2024-06-05 09:00:00 Proposed REX Retail Offer 1,28 EUR | -2,74%  | 1,09 MEUR
2024-06-04 08:00:00 Faron commences a share offering 1,31 EUR | -44,20%  | 2,52 MEUR pdf download
2024-05-20 08:00:00 Initial positive data from Phase 2 of BEXMAB 3,10 EUR | +7,08%  | 1,82 MEUR pdf download
2024-05-17 17:00:00 Issuance of warrants
2024-05-16 08:05:00 Founders named European Inventor Award finalists 2,85 EUR | +1,79%  | 0,53 MEUR pdf download
2024-05-13 08:00:00 Replacement – Board Change 2,41 EUR | -5,68%  | 1,27 MEUR pdf download
2024-04-30 15:00:00 Update on financial status 1,81 EUR | +2,84%  | 0,16 MEUR
2024-04-30 14:00:00 Board Change 1,81 EUR | +2,84%  | 0,16 MEUR pdf download
2024-04-16 08:00:00 Faron confirms plans under new leadership 1,48 EUR | +2,21%  | 0,20 MEUR pdf download
2024-04-15 08:00:00 Appointment of Chief Financial Officer 1,45 EUR | +0,84%  | 0,09 MEUR pdf download
2024-04-08 08:10:00 Approval of Warrant Terms and Conditions 1,52 EUR | 0,00%  | 0,12 MEUR pdf download
2024-04-08 08:05:00 Decisions of the Board of Directors 1,52 EUR | 0,00%  | 0,12 MEUR pdf download
2024-04-08 08:00:00 Appointment of Chief Executive Officer 1,52 EUR | 0,00%  | 0,12 MEUR pdf download
2024-04-05 13:00:00 Results of the Annual General Meeting 1,52 EUR | -2,07%  | 0,07 MEUR
2024-04-04 08:00:00 Announcement of Placing 1,55 EUR | -8,40%  | 5,26 MEUR pdf download
2024-03-28 08:00:00 Issue of Warrants to IPF Funding Update 1,71 EUR | +2,51%  | 0,11 MEUR pdf download
2024-03-26 11:00:00 Faron´s Annual Report 2023 1,70 EUR | -0,35%  | 0,10 MEUR pdf download
2024-03-18 08:00:00 Additional Positive Data from Phase 1 of BEXMAB 2,15 EUR | +20,51%  | 0,42 MEUR pdf download
2024-03-14 08:00:00 Faron to Host BEXMAB Webcast 1,72 EUR | -7,14%  | 0,09 MEUR pdf download
2024-03-13 15:00:00 Notice of Annual General Meeting 2024 1,85 EUR | +13,37%  | 0,14 MEUR
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden